Skip to main content

J&J says its one-shot Covid vaccine is 72% effective in the U.S., but less potent in other regions

The Covid vaccine was well tolerated, with no significant safety concerns related to the vaccine reported, J&J said. There were also no reports of anaphylaxis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.